BLOOD PRESSURE PROCEDURE
How it works
The renal denervation blood pressure procedure provides an additional, complementary management option for people with uncontrolled high blood pressure.1–3
What the renal denervation procedure does
The renal denervation blood pressure procedure calms excessively active nerves connected to the kidneys that may be contributing to high blood pressure.4
An evidence-based option to help reduce blood pressure1-3
- The renal denervation blood pressure procedure is supported by extensive clinical research,1-3 with over 7,000 patients studied,5 and over 10 years of follow-up evidence6
- Works to reduce blood pressure 24 hours a day – unlike daily medications, which rely on taking pills every day to be effective1,2
- Blood pressure was reduced by an average of 18.7mmHg in a three-year study of people who received the procedure and also took medications.7
- Evidence of minimal impact on kidney function8,9
- Over 25,000 people have been treated with the renal denervation blood pressure procedure10
Adverse events include, but are not limited to, bruising and pain. Results may vary.
What is it?
- A single, minimally invasive procedure, performed in a hospital
- Patients may go home the same day, or stay overnight, depending on a doctor’s recommendation
This website is intended to be educational and is not to be used as a diagnostic tool. It is not intended to replace the information provided by healthcare providers and does not constitute medical advice. The information may not be directly applicable for individual clinical circumstances. Please talk with your doctor about diagnosis and treatment information. Always follow the instructions specified by doctors or nursing staff, including discharge instructions after a procedure.
References
1
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomized, sham-controlled trial. The Lancet 2020: Published online March 29, 2020.
2
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet 2018; Jun 9;391(10137): 2346-55.
3
Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet 2017; 390: 2160–70.
4
Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. Nat Rev Cardiol. 2020 Oct;17(10):614-628.
5
Medtronic Data on File. April 2021.
6
Al Ghorani H, Kulenthiran S, Johannes M, et al. 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. . Journal of the American College of Cardiology 2023; 81(5): 517-9.
7
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022;399:1401–1410.
8
Kandzari DE. Renal Denervation In The Presence Of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled Spyral HTN-ON MED Trial. Presented at AHA Conference 2022 2022.
9
Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)European Heart Journal. 2023;44:1313–1330.
10
Medtronic Data on File.; July 2023.